MedTech — Payments to Acquire in Process Research and Development
Business Segments · Payments to Acquire in Process Research and DevelopmentJohnson & Johnson MedTech — Payments to Acquire in Process Research and Development remained flat by 0.0% to $125.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 25.0%, from $100.00M to $125.00M.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2023
Last reportedQ4 2024
How to read this metric
An increase suggests aggressive inorganic growth and investment in future product pipelines, while a decrease may indicate a focus on internal R&D or a pause in external deal-making.
Detailed definition
This metric represents the cash outflows associated with acquiring intellectual property or research projects that have...
Peer comparison
Commonly reported by large-cap medical device and pharmaceutical companies as 'In-Process R&D' or 'IPR&D' acquisition costs.
Metric ID:
jnj_segment_medtech_payments_to_acquire_in_process_research_and_developmentHistorical Data
2 years
| FY'23 | FY'24 | |
|---|---|---|
| Value | $400.00M | $500.00M |
| YoY Change | — | +25.0% |
Range$400.00M – $500.00M
Avg YoY Growth+25.0%
Median YoY Growth+25.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's medtech — payments to acquire in process research and development?
- Johnson & Johnson (JNJ) reported medtech — payments to acquire in process research and development of $125.00M in Q4 2024.
- How has Johnson & Johnson's medtech — payments to acquire in process research and development changed year-over-year?
- Johnson & Johnson's medtech — payments to acquire in process research and development increased by 25.0% year-over-year, from $100.00M to $125.00M.
- What does medtech — payments to acquire in process research and development mean?
- Cash spent to acquire early-stage research projects and intellectual property from external parties.